Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives
- PMID: 12834268
- DOI: 10.1023/a:1024224311289
Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives
Abstract
This review is to summarize experimental evidence and theoretical consideration in support of the concept that a mesencephalic enhancer regulation is the basis of the limited number of innate drives indispensable for the survival of the individual and the species, while a specifically organized telencephalic enhancer regulation is the basis of the acquired drives to reach an unlimited number of dispensable goals. The study is also an overview of the experimental and clinical data supporting the proposal that, due to the progressive decay of the mesencephalic enhancer regulation with the passing of time, the prophylactic administration of a synthetic enhancer substance [(-)-deprenyl, (-)-BPAP] during postdevelopmental life could significantly slow the age-related decay of behavioral performances, prolong life, and prevent the precipitation or delay the onset of Parkinson's disease and Alzheimer's disease.
Similar articles
-
Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.Prog Neuropsychopharmacol Biol Psychiatry. 2004 May;28(3):421-7. doi: 10.1016/j.pnpbp.2003.11.016. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 15093948 Review.
-
Cytoprotective effect of two synthetic enhancer substances, (-)-BPAP and (-)-deprenyl, on human brain capillary endothelial cells and rat PC12 cells.Life Sci. 2006 Aug 8;79(11):1034-9. doi: 10.1016/j.lfs.2006.03.005. Epub 2006 Apr 19. Life Sci. 2006. PMID: 16624331
-
(-)Deprenyl (Selegiline): past, present and future.Neurobiology (Bp). 2000;8(2):179-99. Neurobiology (Bp). 2000. PMID: 11061214 Review.
-
[Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].Neuropsychopharmacol Hung. 2009 Dec;11(4):217-25. Neuropsychopharmacol Hung. 2009. PMID: 20150659 Review. Hungarian.
-
[The feasibility of synthetic enhancer substances for preventive nanotherapy].Neuropsychopharmacol Hung. 2010 Sep;12(3):395-403. Neuropsychopharmacol Hung. 2010. PMID: 20962359 Review. Hungarian.
Cited by
-
Age-related decline of various cognitive functions in well-experienced male rats treated with the putative anti-aging compound (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine ((-)BPAP).Geroscience. 2024 Feb;46(1):417-429. doi: 10.1007/s11357-023-00821-6. Epub 2023 Jun 12. Geroscience. 2024. PMID: 37306892 Free PMC article.
-
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).Mol Psychiatry. 2016 Nov;21(11):1499-1503. doi: 10.1038/mp.2016.127. Epub 2016 Aug 2. Mol Psychiatry. 2016. PMID: 27480491 Review.
-
The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats.Neuropsychiatr Dis Treat. 2008 Aug;4(4):687-99. doi: 10.2147/ndt.s3272. Neuropsychiatr Dis Treat. 2008. PMID: 19043511 Free PMC article.
-
Regulation by Trace Amine-Associated Receptor 1 (TAAR1) of Dopaminergic-GABAergic Interaction in the Striatum: Effects of the Enhancer Drug (-)BPAP.Neurochem Res. 2025 Feb 4;50(2):94. doi: 10.1007/s11064-025-04337-7. Neurochem Res. 2025. PMID: 39903411 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources